Patents by Inventor Guido Marcucci

Guido Marcucci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MICRORNA AS A THERAPEUTIC AGENT
    Publication number: 20230220385
    Abstract: The disclosure provides, inter alia, hybridized nucleic acid sequences and compounds comprising Toll-like receptor 9-binding nucleic acid sequences and nucleic acid sequences comprising a microRNA passenger strand sequence hybridized to a microRNA guide strand sequence; pharmaceutical compositions comprising the hybridized nucleic acid sequences and compounds; and the use of the hybridized nucleic acid sequences, compounds, and pharmaceutical compositions to treat medical conditions, such as cancer and inflammatory diseases.
    Type: Application
    Filed: November 25, 2020
    Publication date: July 13, 2023
    Inventors: Marcin Tomasz Kortylewski, Guido Marcucci, Yu-Lin Su, Piotr Marek Swiderski
  • Conditional-siRNAS and uses thereof in treating acute myeloid leukemia
    Patent number: 11643659
    Abstract: Disclosed herein are conditional siRNAs activatable by CBF?-MYH11 oncogenic gene and use thereof for treating conditions such as acute myeloid leukemia (AML). The conditional siRNAs target MCL-1 or HDAC8.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: May 9, 2023
    Assignees: CITY OF HOPE, CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Guido Marcucci, Ya-Huei Kuo, Si-ping Han, Lisa Scherer, William A. Goddard, III, John Rossi
  • ANTI-IL1RAP ANTIBODIES
    Publication number: 20230081443
    Abstract: Provided herein are, inter alia, antibodies capable of binding Interleukin-1 receptor accessory protein (IL1RAP). The antibodies provided herein include novel light chain and heavy chain sequences and bind IL1RAP with high efficiency and specificity. The anti-IL1RAP antibodies provided herein are, inter alia, useful for the treatment of IL1RAP-expressing cancers such as AML.
    Type: Application
    Filed: June 28, 2022
    Publication date: March 16, 2023
    Inventors: Weixu MENG, Guido MARCUCCI
  • Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
    Patent number: 11591596
    Abstract: The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: February 28, 2023
    Assignee: City of Hope
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Guido Marcucci, Bin Zhang, Ya-Huei Kuo
  • IL1RAP ANTIBODIES
    Publication number: 20220306750
    Abstract: Provided herein are, inter alia, Interleukin-1 receptor accessory protein (IL1RAP) antibodies and fragments thereof which may form part of chimeric antigen receptors or bispsecific antibodies and are useful for treating IL1RAP-expressing cancers.
    Type: Application
    Filed: August 12, 2020
    Publication date: September 29, 2022
    Inventors: Bin Zhang, Weixu Meng, Guido Marcucci
  • Anti-IL1RAP antibodies
    Patent number: 11370842
    Abstract: Provided herein are, inter alia, antibodies capable of binding Interleukin-1 receptor accessory protein (IL1RAP). The antibodies provided herein include novel light chain and heavy chain sequences and bind IL1RAP with high efficiency and specificity. The anti-IL1RAP antibodies provided herein are, inter alia, useful for the treatment of IL1RAP-expressing cancers such as AML.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: June 28, 2022
    Assignee: CITY OF HOPE
    Inventors: Weixu Meng, Guido Marcucci
  • Methods for suppressing cancer-related cachexia
    Patent number: 11219607
    Abstract: Methods of suppressing cachexia in a mammal with cancer comprising administering HDAC inhibitors are provided. Aspects include methods of administering an HDAC class 1 and 2b inhibitor in an amount effective to substantially maintain the mammal's weight compared to a mammal that does receive the HDAC class 1 and 2b inhibitor.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: January 11, 2022
    Assignee: OHIO STATE INNOVATION FOUNDATION
    Inventors: Ching-Shih Chen, Tanios Bekaii-Saab, Denis Guttridge, Guido Marcucci, Samuel Kulp, Yu-Chou Tseng
  • CONDITIONAL-siRNAS AND USES THEREOF IN TREATING ACUTE MYELOID LEUKEMIA
    Publication number: 20210123060
    Abstract: Disclosed herein are conditional siRNAs activatable by CBF?-MYH11 oncogenic gene and use thereof for treating conditions such as acute myeloid leukemia (AML). The conditional siRNAs target MCL-1 or HDAC8.
    Type: Application
    Filed: February 10, 2020
    Publication date: April 29, 2021
    Applicants: CITY OF HOPE, CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Guido MARCUCCI, Ya-Huei KUI, Si-ping HAN, Lisa SCHERER, William A. GODDARD, III, John ROSSI
  • COMPOUNDS AND COMPOSITIONS INCLUDING PHOSPHOROTHIOATED OLIGODEOXYNUCLEOTIDE, AND METHODS OF USE THEREOF
    Publication number: 20210115443
    Abstract: The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.
    Type: Application
    Filed: September 2, 2020
    Publication date: April 22, 2021
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Guido Marcucci, Bin Zhang, Ya-Huei Kuo
  • Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
    Patent number: 10801026
    Abstract: The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: October 13, 2020
    Assignee: CITY OF HOPE
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Guido Marcucci, Bin Zhang, Ya-Huei Kuo
  • METHODS OF USING ANTI-MIR126 COMPOUNDS
    Publication number: 20200281982
    Abstract: Provided herein are, inter alia, methods of treating red blood cell disorders and cancer using anti-miR126 compounds. The methods include administering phosphorothioated CpG oligodeoxynucleotides conjugated to an anti-miR126 nucleic acid sequence to treat red blood cell disorders. Other methods provided herein include administering phosphorothioated CpG oligodeoxynucleotides conjugated to an anti-miR126 nucleic acid sequence and a tyrosine kinase inhibitor to treat cancer.
    Type: Application
    Filed: March 5, 2020
    Publication date: September 10, 2020
    Inventors: Guido Marcucci, Bin Zhang, Ya-Huei Kuo, Marcin Tomasz Kortylewski
  • ANTI-IL1RAP ANTIBODIES
    Publication number: 20200247893
    Abstract: Provided herein are, inter alia, antibodies capable of binding Interleukin-1 receptor accessory protein (IL1RAP). The antibodies provided herein include novel light chain and heavy chain sequences and bind IL1RAP with high efficiency and specificity. The anti-IL1RAP antibodies provided herein are, inter alia, useful for the treatment of IL1RAP-expressing cancers such as AML.
    Type: Application
    Filed: August 1, 2018
    Publication date: August 6, 2020
    Inventors: Weixu MENG, Guido MARCUCCI
  • Boronic acid esters and pharmaceutical formulations thereof
    Patent number: 10167311
    Abstract: Provided herein are boronic acid esters of boronic acid therapeutic agents, such as bortezomib. The boronic acid esters can be used to prepare liposomal formulations of boronic acid therapeutic agents with improved properties, such as enhanced stability. This disclosure, in one aspect, relates to compositions and methods of making and using the compositions.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: January 1, 2019
    Assignee: Ohio State Innovation Foundation
    Inventors: Michael Caligiuri, Robert Lee, Guido Marcucci
  • COMPOUNDS AND COMPOSITIONS INCLUDING PHOSPHOROTHIOATED OLIGODEOXYNUCLEOTIDE, AND METHODS OF USE THEREOF
    Publication number: 20180312837
    Abstract: The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.
    Type: Application
    Filed: October 14, 2016
    Publication date: November 1, 2018
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Guido Marcucci, Bin Zhang, Ya-Huei Kuo
  • BORONIC ACID ESTERS AND PHARMACEUTICAL FORMULATIONS THEREOF
    Publication number: 20160347791
    Abstract: Provided herein are boronic acid esters of boronic acid therapeutic agents, such as bortezomib. The boronic acid esters can be used to prepare liposomal formulations of boronic acid therapeutic agents with improved properties, such as enhanced stability. This disclosure, in one aspect, relates to compositions and methods of making and using the compositions.
    Type: Application
    Filed: February 3, 2015
    Publication date: December 1, 2016
    Inventors: Michael Caligiuri, Robert Lee, Guido Marcucci
  • METHODS FOR SUPPRESSING CANCER-RELATED CACHEXIA
    Publication number: 20150150832
    Abstract: Methods of suppressing cachexia in a mammal with cancer comprising administering HDAC inhibitors are provided. Aspects include methods of administering an HDAC class 1 and 2b inhibitor in an amount effective to substantially maintain the mammal's weight compared to a mammal that does receive the HDAC class 1 and 2b inhibitor.
    Type: Application
    Filed: November 19, 2014
    Publication date: June 4, 2015
    Inventors: Ching-Shih Chen, Tanios Bekaii-Saab, Denis Guttridge, Guido Marcucci, Samuel Kulp, Yu-Chou Tseng
  • Therapeutic agents for the treatment of leukemia
    Patent number: 8633161
    Abstract: The invention provides for methods of treating a mammal who has a BCR/ABL-mediated leukemia, including chronic myelogenous leukemia (CML), particularly the blast crisis stage of CML, Philadelphia-positive acute lymphoblastic leukemia (Ph?-ALL), and refractory leukemias. The invention also provides for compounds for the treatment of these leukemias and methods of identifying anti-leukemic agents.
    Type: Grant
    Filed: March 24, 2006
    Date of Patent: January 21, 2014
    Assignee: The Ohio State University Research Foundation
    Inventors: Danilo Perrotti, Paolo Neviani, Ramasamy Santhanam, John C. Byrd, Guido Marcucci, Natarajan Muthusamy, Ching-Shih Chen
  • Hybridization Quantitation Method for Modified Micro-RNA and -DNA Based Oligonucleotides
    Publication number: 20110027798
    Abstract: Described herein is a method for the qualitative and/or quantitative determination of an analyte in a test sample which includes base pairing at least one oligonucleotide to a capture template having an overhang; and, hybridizing with a detection probe.
    Type: Application
    Filed: March 31, 2009
    Publication date: February 3, 2011
    Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Kenneth K. Chan, Zhongfa Liu, Zhiliang Xie, Guido Marcucci, John C. Byrd, Natarajan Muthusamy, Ramiro Garzon, Shujun Lui
  • THERAPEUTIC AGENTS FOR THE TREATMENT OF LEUKEMIA
    Publication number: 20100256072
    Abstract: The invention provides for methods of treating a mammal who has a BCR/ABL-mediated leukemia, including chronic myelogenous leukemia (CML), particularly the blast crisis stage of CML, Philadelphia-positive acute lymphoblastic leukemia (Ph?-ALL), and refractory leukemias. The invention also provides for compounds for the treatment of these leukemias and methods of identifying anti-leukemic agents.
    Type: Application
    Filed: March 24, 2006
    Publication date: October 7, 2010
    Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Danilo Perrotti, Paolo Neviani, Ramasamy Santhanam, John C. Byrd, Guido Marcucci, Natarajan Muthusamy, Ching-Shih Chen